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Summary
Increased Apolipoprotein D (ApoD) expression has
been reported in various neurological disorders, includ-
ing Alzheimer’s disease, schizophrenia, and stroke, and
in the aging brain [1]. However, whether ApoD is toxic or
a defense is unknown. In a screen to identify genes that
protect Drosophila against acute oxidative stress, we
isolated a fly homolog of ApoD, Glial Lazarillo (GLaz).
In independent transgenic lines, overexpression of
GLaz resulted in increased resistance to hyperoxia
(100% O2) as well as a 29% extension of lifespan under
normoxia. These flies also displayed marked improve-
ments in climbing and walking ability after sublethal
exposure to hyperoxia. Overexpression of Glaz also in-
creased resistance to starvation without altering lipid
or protein content. To determine whether GLaz might
be important in protection against reperfusion injury,
we subjected the flies to hypoxia, followed by recovery
under normoxia. Overexpression of GLaz was protec-
tive against behavioral deficits caused in normal flies
by this ischemia/reperfusion paradigm. This and the
accompanying paper by Sanchez et al. [2] (in this issue
ofCurrent Biology) are the first to manipulate the levels
of an ApoD homolog in a model organism. Our data sug-
gest that human ApoD may play a protective role and
thus may constitute a therapeutic target to counteract
certain neurological diseases.
Results
Overexpression of GLaz Confers Resistance
to Hyperoxia, as Well as Lifespan Extension
in Normoxia
Oxidative stress has been widely implicated as an un-
derlying mechanism in the pathology of neurodegenera-
tive disorders, including Alzheimer’s disease (AD) and
schizophrenia [3, 4], as well as in the injury resulting
from stroke [5]. In addition, an overwhelming body of
evidence supports the idea that reactive oxygen species
(ROS) are a major cause of aging [6]. As the formation of
ROS is a function of ambient oxygen concentration [7],
exposure to hyperoxia (100% O2) offers an attractive
model for physiological studies of oxidative stress.
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that confer increased resistance to hyperoxia. This and
all the subsequent experiments in this report were per-
formed with male flies only. We drove high-level expres-
sion of various genes by crossing enhancer promoter
(EP) element lines [8] having known insertion sites with
a driver line providing a ubiquitous GAL4 source, namely
daughterless (da-GAL4). One of the lines, EP(2)2383,
carrying an insertion on the second chromosome, dis-
played a striking GAL4-dependent phenotype and was
chosen for further study. Flies carrying both EP(2)2383
and da-GAL4 are much more resistant to hyperoxia (Fig-
ure 1A). The insertion in EP(2)2383 is 1.5 kb upstream
of Glial Lazarillo (GLaz). RT-PCR confirmed that the
EP(2)2383 insertion causes a GAL4-dependent upregu-
lation of theGLaz transcript (see Figure S1 in the Supple-
mental Data available with this article online). A microar-
ray showed a 7-fold upregulation of the GLaz transcript,
while nearby genes (NrkI, TppII, SptI, and CG17724) in
the genomic region were not affected (data not shown).
Glial Lazarillo (Glaz) is aDrosophila homolog of human
Apolipoprotein D (ApoD), with 40% identity and 80%
similarity to the human protein. Both are predicted to
be very similar to the ancestral proteins that gave rise
to the lipocalin family [9–11]. These are cup-shaped sol-
uble molecules, able to carry hydrophobic ligands in a
1:1 molar ratio. The physiological ligand for ApoD is un-
determined, although, based on binding studies, arachi-
donic acid and steroids are the best candidates [12]. In
Alzheimer’s disease, both mRNA and protein levels of
ApoD are dramatically increased (350% in the cerebro-
spinal fluid), and the protein is recruited to the amyloid
plaques [13–15]. After crush injury of the rat sciatic
nerve, regeneration is accompanied by a 500-fold upreg-
ulation of ApoD at the site of the lesion for several weeks
after the injury [16, 17]. Neuronal degeneration induced
by kainic acid triggers an upregulation of ApoD in the af-
fected area [18]. An increase in ApoD expression has
been detected in a murine model of Niemann-Pick dis-
ease type C (NPC), an inherited lysosomal cholesterol
disorder [19]. Elevated ApoD expression has been re-
ported in schizophrenia and bipolar disorder [20].
ApoD levels have also been reported to increase with
aging in both humans and mice [15, 21].
In general, there is a strong correlation between resis-
tance to oxidative stress and increased longevity [6].
Therefore, we measured the lifespan under normoxia
of flies carrying EP(2)2383 and da-GAL4. Overexpres-
sion of GLaz led to an increase in mean lifespan at
29ºC of 18% (p < 0.001, Figure 1B).
Tissue-Specific Overexpression of GLaz
To study the overexpression further and confirm whether
overexpressing GLaz was sufficient to cause the life-
span extension, we generated independent transgenic
lines carrying the Glaz cDNA under GAL4 regulation.
The complete Glaz cDNA was cloned in the pUAST vec-
tor, thereby placing the insert under the control of UAS
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675Figure 1. Increase in Hyperoxia Resistance and Extension of Lifespan by Overexpression of GLaz
(A) Survival under hyperoxia (100% O2). da-GAL4 (ubiquitous GAL4 driver) is used to activate the UAS sequences in EP(2)2383. Each graph rep-
resents a trial with at least 100 flies, typical of several repeated experiments. The EP overexpressor (w1118; EP(2)2383/+; da-GAL4/+, red curve)
lives 20% longer (p < 0.001) than the driver control (w1118; da-GAL4/+, black curve). The dotted line represents the EP alone (w1118; EP2383/+).
(B) At 29ºC, under normoxia, the EP overexpressor lives 18% longer than driver control.sequences within the boundaries of a P element. Two in-
dependent transformants were generated (UAS-GLaz1
and UAS-GLaz2), both on the second chromosome.
RT-PCR confirmed that both lines displayed GAL4-
dependent upregulation of the Glaz transcript (Fig-
ure S2). Based on its relatively higher level of inducibilty,
UAS-GLaz2 was selected for further studies.
To address whether specific tissues are responsible
for the lifespan extension, UAS-GLaz2 and EP(2)2383
were crossed with GAL4 drivers having preferential pat-
terns of expression in various tissues. Since GAL4 gen-
erally yields stronger effects at 29ºC [22], we chose to
perform these experiments at that temperature. The
control used was w1118, the host strain in which both
UAS-Glaz contructs were generated. The results are
outlined in Table 1. As a rule, the driver controls ex-
hibited longer lifespans than the EP or transgenic con-
trols, presumably due to hybrid vigor. Therefore, we sys-
tematically used the driver control as the reference
lifespan for the percentage increase. Best results were
obtained with relatively weak nervous system expres-
sion, combined with some expression in thoracic or ab-
dominal muscles (PO163-GAL4, GAL4109(2)80). Drivers
with expression primarily in the fat or in the muscles
(DJ634, 24B) caused extension of lifespan, as comparedto the control crosses tow1118.GMR-GAL4 also induced
a robust extension of lifespan. Although the latter is
commonly described as an eye-specific driver, we
note that it also drives strong expression of a reporter
in the salivary gland. When either the EP line or the
cDNA transgene was driven by strong nervous system
drivers D42-GAL4 or Elav-GAL4, there was no beneficial
effect. No lifespan extension was observed with Actin-
GAL4 orHsp70-GAL4when driving the cDNA transgene,
although Actin-GAL4 did give a notable extension of
lifespan when driving the EP line.
One of the drivers, GAL4109(2)80, resulted in a particu-
larly strong extension of lifespan with both the EP and
the cDNA line. GAL4109(2)80 is expressed especially in
cells in the thoracic ganglion and the brain and in the
vertical flight muscles of the thorax (Figure 2A). While
this pattern is maintained throughout adulthood (L. Se-
roude, personal communication), during development
it is expressed in only a small subset of sensory neurons
[23]. Flies carryingGAL4109(2)80 and EP(2)2383 displayed
a 29% increase in mean lifespan compared with the
driver crossed to w1118 (Figure 2B), while driving UAS-
GLaz2 resulted in a 23% increase (Figure 2C).
Flies carrying both GAL4109(2)80 and UAS-GLaz2 dis-
played a 12% increase in survival under hyperoxiaTable 1. Lifespan Analysis of Tissue-Specific GAL4 Driver Lines
Control (w1118)
GLaz Overexpressor (EP(2)2383) GLaz Overexpressor (UAS-GLaz2)
Driver Mean 6 SEM Mean 6 SEM % Diff Mean 6 SEM % Diff
CNS/muscle PO163 25.6 6 0.6 30.4 6 0.6 18%, p < 0.001 27.8 6 0.8 8%, p < 0.001
GAL4109(2)80 25.3 6 0.6 32.5 6 0.5 29%, p < 0.001 31.0 6 0.5 23%, p < 0.001
Fat/muscle DJ634 22.8 6 0.6 26.6 6 0.6 17%, p < 0.001 26.5 6 0.6 16%, p < 0.001
24B 23.2 6 0.5 25.5 6 0.6 10%, p < 0.001 29.7 6 0.7 28%, p < 0.001
Eye/salivary gland GMR 25.4 6 0.6 31.0 6 0.3 22%, p < 0.001 31.5 6 0.4 23%, p < 0.001
Ubiquitous Actin 25.6 6 0.8 30.9 6 0.5 21%, p < 0.001 26.6 6 0.5 4%, n.s.
Hsp70 30.3 6 0.5 30.3 6 0.5 0%, n.s. 29.9 6 0.5 21%, n.s.
Neuronal Elav 31.0 6 0.6 31.4 6 0.7 1%, n.s. 29.3 6 0.6 25%, n.s.
D42 20.2 6 0.5 19.1 6 0.5 25%, n.s. 21.1 6 0.8 4%, n.s.
The different drivers are grouped by expression patterns. The first column shows the mean lifespan6SEM of each driver alone (crossed tow1118)
as controls. The second column shows the mean lifespan6SEM of the various drivers crossed to EP(2)2383, and the percentage difference with
the driver control (n.s. = not significant). The third column displays the same information for each driver crossed to the transgenic cDNA insertion
line UAS-GLaz2. Drivers that did not have a strong expression during development all gave good extensions of lifespan. The same drivers that
extended lifespan of the EP line also increased lifespan of the cDNA transgenic line, with the exception of Actin-GAL4.
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676Figure 2. Protection against Hyperoxia and Extension of Lifespan by Overexpression of GLaz with GAL4109(2)80 as the Driver
(A) X-GAL staining of a horizontal cryosection showing the adult expression pattern of the driver, with nuclear-LacZ under UAS control as a re-
porter. In the thorax, GAL4109(2)80 is expressed in the two vertical flight muscles (green dotted line) and in cells of the ventral ganglion (red dotted
line). In the head, the driver is expressed predominantly in the retina and optic lobes (red arrows) and central brain areas (green arrow).
(B) EP line lifespan extension under normoxia, at 29ºC. GLaz EP overexpressors (w1118; GAL4109(2)80/EP(2)2383, red curve) live 23% longer (p <
0.001) than driver control (w1118; GAL4109(2)80/+, black curve). The dotted line represents the EP alone (w1118; EP(2)2383/+).
(C) GLaz cDNA transgenic lifespan extension under normoxia, at 29ºC. GLaz cDNA overexpressors (w1118; GAL4109(2)80/UAS-GLaz2, red curve)
live 23% longer (p < 0.001) than driver control (w1118; GAL4109(2)80/+, black curve). The dotted line represents the transgene alone (w1118; UAS-
GLaz2/+).
(D) GAL4-dependent lifespan extension under hyperoxia in the transgenic flies. GLaz cDNA overexpressors (w1118; GAL4109(2)80/UAS-GLaz2, red
curve) live 12% longer (p < 0.001) than the driver control (w1118; GAL4109(2)80/+, black curve). Each graph represents a trial with at least 100 flies,
typical of several repeated experiments.(Figure 2D) compared to the driver control. To test
whether the overexpressor flies also had improved vigor
associated with their hyperoxia resistance, we per-
formed behavioral assays. After 4 days in hyperoxia,
both vertical and horizontal locomotor performances
were much better in flies overexpressing GLaz, as com-
pared to controls (Figures 3A and 3B). The same geno-
types, when maintained under normoxia, showed no
differences.
Flies Overexpressing Glaz Are More Resistant
to Starvation
Resistance to multiple extrinsic stressors is a hallmark
of several long-lived mutants [24]. We tested flies over-
expressing GLaz for resistance to wet or dry starvation.
Overexpression of Glaz led to a 60% increase in lifespan
under wet starvation (Figure 4A) and a 30% increase un-
der dry starvation (Figure 4B). Given the predicted na-
ture of the protein as a secreted lipid carrier, we checked
whether the flies overexpressing GLaz were larger or
displayed higher lipid or protein content. There was no
significant difference in dry weight (Figure S3A), protein
content (Figure S3B), or fat content (Figure S3C) be-
tween flies overexpressing GLaz and the driver crossed
to w1118.GLaz Overexpression Protects against Behavioral
Deficits Caused by Hypoxia
ApoD is upregulated in a mouse model of stroke [25].
Therefore, we tested the ability of flies that overexpress
Glaz to withstand periods of oxygen deprivation, fol-
lowed by recovery under normoxia. The flies were sub-
jected to hypoxia in 100% N2 for 30 min, then transferred
back to a normoxic environment. After awakening, flies
overexpressing Glaz were much more active than con-
trol flies. In our assay of vertical locomotion perfor-
mance, 1 hr after their recovery, 75% of the GLaz over-
expressors climbed to the top third of the vial, while
only 10%–15% of control flies managed to do the same
(Figure 4C). This difference was still evident 2 days later.
Before hypoxia exposure, no difference in climbing abil-
ity was observed.
Discussion
We report that overexpression of GLaz, by means of
independent EP insertions or transgenic lines, can result
in increased resistance to stress and extension of life-
span. These results are consistent with ApoD being part
of a damage-control system. The mechanisms involved
in these effects remain to be determined: GLAZ, and
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677Figure 3. Overexpression of Glaz Protects against Hyperoxia-Induced Behavioral Decline
(A) Assay of vertical locomotion performance before (white bars) and after (black bars) 4 days under hyperoxia. After hyperoxia, flies overex-
pressing GLaz (w1118; GAL4109(2)80/UAS-GLaz2) climbed significantly better than either control (w1118; GAL4109(2)80/+ or w1118; UAS-GLaz2/+,
Student’s t test, p < 0.001).
(B) Assay of horizontal locomotion performance before (white bars) and after (black bars) 4 days under hyperoxia. Flies overexpressing GLaz
(w1118; GAL4109(2)80/UAS-GLaz2) performed significantly better than controls (w1118; GAL4109(2)80/+ or w1118; UAS-GLaz2/+, Student’s t test,
p < 0.001). Error bars represent SEM.perhaps APOD, may transport lipophilic molecules to
and from cells, thus helping to repair damaged mem-
branes or clear cholesterol and fatty acids released by
dying cells. In mammals, the binding affinity for arachi-
donic acid may point to a role in the control of
inflammation. They may also quench deleterious mole-
cules such as lipid peroxides or scavenge other free rad-
icals. In the accompanying paper, Sanchez et al. [QA]
observe a depletion of lipid stores in GLaz-deficient mu-
tants. GLAZ may work as part of a shuttle system, used
to maintain stores at a normal level, while providing sup-
port to other tissues in situations of stress.
We screened multiple drivers, with multiple responder
lines, and could not point to a single tissue as a neces-
sary or sufficient site of upregulation to produce in-
creased longevity. The amount of overexpression of
such a secreted protein may matter more than its site of
production. Furthermore, it must be kept in mind that
the expression patterns of many drivers change during
development and with age and that GLaz is likely to be
secreted. Interestingly, overexpression with strong neu-
ronal drivers did not extend adult lifespan. In the accom-
panying paper, Sanchez et al. [QA] report that normal
adult expression of GLaz is primarily in glial cells, and
to some extent in the cardia and hemocytes. In embryos,
the transcript is present in the nervous system [11] and
the developing gut. In the embryonic nervous system,
Glaz is expressed in the longitudinal glia. These cells
are known to be crucial for axon guidance and neuronal
trophic support and can be considered homologous tooligodendrocytes of vertebrates. Originally, the grass-
hopper homolog, Lazarillo, was found to be important
for axon guidance [26]. One of our most effective drivers,
GAL4109(2)80, is expressed in adult vertical flight mus-
cles, and, to a lesser extent, in the adult nervous system,
but has a very restricted expression pattern during de-
velopment. It is therefore possible that strong early
overexpression in neurons has adverse effects that
mask the benefits of GLAZ in the adult, where it may cir-
culate in the hemolymph to reach its target tissues.
Flies overexpressing Glaz fared much better in behav-
ioral tests after hyperoxia exposure. We have recently
shown that the flight muscle is one of the earliest tissues
to suffer damage under hyperoxia and that old flies also
display some of the alterations seen under hyperoxic
stress [27]. It is conceivable that overexpression of
GLaz in the flight muscles (via GAL4109(2)80) is beneficial
either by improving nutrient exchange or by delaying
cellular damage. In the mouse, ApoD is upregulated in
response to cerebral stroke [25]. Some of the common
therapies for victims of such damage aim at lowering
the overall metabolism of the affected area to decrease
the oxidative burden on cells. We show that GLaz over-
expression can protect against behavioral decline in-
duced by exposure to hypoxia. GLaz overexpression
might make the flies more resistant to the cellular insult
of the stresses studied here, thus hastening recovery.
In recent years, Drosophila has become a powerful
model for studying neurodegenerative disorders [28].
Understanding how lipocalins regulate lifespan or
Current Biology
678Figure 4. Overexpression of Glaz Increases Resistance to Multiple Extrinsic Stresses
(A) Wet starvation. Flies overexpressing GLaz (w1118; GAL4109(2)80/UAS-GLaz2, red curve) lived 60% longer than driver controls (w1118;
GAL4109(2)80/+, p < 0.001).
(B) Dry starvation (desiccation). Flies overexpressing GLaz (w1118; GAL4109(2)80/UAS-GLaz2) lived 30% longer than driver controls (w1118;
GAL4109(2)80/+, p < 0.001). Dotted line represent the transgene alone (w1118; UAS-GLaz2/+). Each graph represents a trial with at least 100 flies,
typical of several repeated experiments.
(C) Hypoxia. Assay of vertical locomotion performance after 30 min under hypoxia, followed by 1 hr recovery under normoxia. White bars rep-
resent performance before hypoxia exposure, with no significant difference between genotypes. Black bars represent performance after hypoxia
exposure and recovery: flies overexpressing GLaz (w1118; GAL4109(2)80/UAS-GLaz2) climbed significantly better (Student’s t test, p < 0.001) than
either controls (w1118; GAL4109(2)80/+ or w1118; UAS-GLaz2/+). Error bars represent SEM.rescue neurological disorders in Drosophila may help to
understand the role of ApoD in the human brain and sug-
gest ways of manipulating its expression and function,
providing clues to potential therapeutic routes.
Supplemental Data
Supplemental Data include three figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.current-biology.com/cgi/content/full/16/7/674/DC1/.
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